Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.
about
Vaccines against malariaAdvances and challenges in malaria vaccine developmentUse of massively parallel pyrosequencing to evaluate the diversity of and selection on Plasmodium falciparum csp T-cell epitopes in Lilongwe, MalawiProduction of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemVaccines for malaria: how close are we?Malaria Parasites: The Great EscapeAbsolute Quantification of the Host-To-Parasite DNA Ratio in Theileria parva-Infected Lymphocyte Cell LinesMeasurement of the plasma levels of antibodies against the polymorphic vaccine candidate apical membrane antigen 1 in a malaria-exposed populationPhase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsDiversity of T cell epitopes in Plasmodium falciparum circumsporozoite protein likely due to protein-protein interactions.Differing patterns of selection and geospatial genetic diversity within two leading Plasmodium vivax candidate vaccine antigens.Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in AfricaVariation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications.Distinct patterns of diversity, population structure and evolution in the AMA1 genes of sympatric Plasmodium falciparum and Plasmodium vivax populations of Papua New Guinea from an area of similarly high transmissionFungalRV: adhesin prediction and immunoinformatics portal for human fungal pathogens.The Jeremiah Metzger lecture: new additions to the toolbox for global malaria eradication.Strategies for designing and monitoring malaria vaccines targeting diverse antigensLack of allele-specific efficacy of a bivalent AMA1 malaria vaccineDisease progression in Plasmodium knowlesi malaria is linked to variation in invasion gene family membersMultiple antigen peptide vaccines against Plasmodium falciparum malariaAllelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in KenyaLimited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.Blood stage vaccines for Plasmodium falciparum: current status and the way forward.Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria.Global Population Structure of the Genes Encoding the Malaria Vaccine Candidate, Plasmodium vivax Apical Membrane Antigen 1 (PvAMA1).Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.Seroreactivity to a large panel of field-derived Plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 variants reflects seasonal and lifetime acquired responses to malaria.No recent adaptive selection on the apyrase of Mediterranean Phlebotomus: implications for using salivary peptides to vaccinate against canine leishmaniasis.A field trial to assess a blood-stage malaria vaccine.Genetic diversity and population structure of genes encoding vaccine candidate antigens of Plasmodium vivax.Evolution of the Transmission-Blocking Vaccine Candidates Pvs28 and Pvs25 in Plasmodium vivax: Geographic Differentiation and Evidence of Positive SelectionA novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens.Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens.Pooled Amplicon Deep Sequencing of Candidate Plasmodium falciparum Transmission-Blocking Vaccine Antigens.
P2860
Q17485685-9CA98BC4-19B9-4715-9878-3D47CE44F930Q21032463-385B0C62-9663-4FA5-A8F8-F7D7B225291DQ24617275-2BE859D2-74B0-4D58-9F12-C838E29A2CA4Q26700012-BDBD55F9-1685-43CA-9708-3C917D19B768Q27024344-05CEE5AF-FD4D-453D-839C-E2A77B083B6CQ28080325-AA7778AD-17F8-4EC9-99CF-72DC6B802E37Q28603519-8539022A-742C-41F7-A4E8-2B150DD3B5DCQ28730794-A84B18D8-2BE0-46C4-8231-5F3F06BC3B68Q28731894-E8FB8A0B-1011-424E-9EA2-8D996C1E084AQ30430387-C11BAF88-A54E-4419-8100-9DEB2EF5F00EQ30439881-782C2830-84EA-4805-AB2E-4136509E2524Q33530106-9CC8948F-9635-4A10-95AE-938C8295B891Q33828802-9BE36A0E-2C5B-472B-851E-1FB66BB1325FQ33846126-D37D780E-0DDA-400F-B3D4-B8592C41D8C8Q33859217-CAB1585F-BBD1-4950-90D5-FE01BE52C6C4Q33874270-CEAA6639-C8A2-402D-9AF0-74788E9DBB32Q33957657-B6DEEEE6-57F0-42B8-9C08-ABD559993DC5Q33959038-447DEB2A-33FC-4259-9833-3036DF030542Q34011922-B43F224C-5101-4420-A305-E23F77C8A779Q34046712-0FC05991-21BA-448D-BABD-928F4320694BQ34290800-67DF0B54-F7A6-4406-B4AD-7CE092323F03Q34290806-64EFF001-4256-4802-8537-0D0FBD5ABBD5Q34416904-AD691AC8-DD51-4A5A-9759-4DA3EE6ED067Q34441098-E17DB881-B933-4E31-8F87-2DD61A39D9E1Q34507190-EEE1C4E5-3776-42AE-9D16-4256C6D47674Q34596157-5FB029C9-4D23-4ADD-A950-19F203B999B3Q34663978-16002921-E2D6-43F9-9C99-2FDA972127D9Q34827195-A079C0E0-6B41-423E-B5E9-795CC2873647Q35037036-A7CF2DEB-0D87-4DEB-80E4-0016C7C23D3FQ35048336-C898DF2D-CE55-43F7-83EF-F6994C393C9AQ35079832-27BB01F0-AB1A-4462-8A0E-01B63B534BF5Q35140646-5672345F-2944-4875-9861-DC066F28E4C8Q35539678-89C87C15-0288-4301-AB6E-B9124EA78690Q35622737-9097917F-6EBC-405C-B6D7-8737FA3669AAQ35898837-ED847F05-2C43-4CD5-86D9-3530DE09AEB3Q36062237-03F780A6-B0EB-4DCF-926E-2CAFE05D59E9Q36141540-F3F85EA2-E29F-4953-999C-2E1EE5F3A163Q36304234-0D71E9EE-855D-4B97-A36E-BBE93AAAB2F3Q36384456-AE0678D9-335E-4D49-BDC8-135597C88EB6Q36455757-5A02674A-5CA9-403B-85DB-FDDE49EF1B23
P2860
Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Extreme polymorphism in a vacc ...... tions for vaccine development.
@ast
Extreme polymorphism in a vacc ...... tions for vaccine development.
@en
type
label
Extreme polymorphism in a vacc ...... tions for vaccine development.
@ast
Extreme polymorphism in a vacc ...... tions for vaccine development.
@en
prefLabel
Extreme polymorphism in a vacc ...... tions for vaccine development.
@ast
Extreme polymorphism in a vacc ...... tions for vaccine development.
@en
P2093
P2860
P50
P1476
Extreme polymorphism in a vacc ...... tions for vaccine development.
@en
P2093
Adrian H Batchelor
Amed Ouattara
Ananias A Escalante
Karim Traoré
Michael P Cummings
Shannon L Takala
P2860
P356
10.1126/SCITRANSLMED.3000257
P407
P50
P577
2009-10-01T00:00:00Z